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Standfirst 
Matta et al.1 reported that men with prostate cancer treated by surgery or radiation therapy had 
greater odds of receiving anti-depressants compared to controls, however this was not observed for 
men on active surveillance.  Caution in interpreting this study as supporting a psychological benefit 
for men on active surveillance compared to active treatment is needed given methodological 
limitations. Screening for distress in men with prostate cancer and referral to evidence-based 
intervention should be a priority for urologic oncology. 
 
Refers to Matta, R. et al. Variation and trends in antidepressant prescribing for men undergoing 
treatment for nonmetastatic prostate cancer: a population-based cohort study. Eur Urol 
https://doi.org/10.1016/j.eururo.2018.08.035 (2018). 
 
  
 A recently published report by Matta et al.1 exploring the  use of antidepressants among men with 
nonmetastatic prostate cancer compared with propensity-score-matched members of the general 
population  is timely given the increasing recognition over the past decade of the psychological toll 
associated with the diagnosis and treatment of this disease. Intriguingly, men with prostate cancer 
treated actively through surgery or radiation therapy had greater odds of receiving anti-depressants 
(peaking at two years) compared to controls, however this effect was not observed for men who were 
on active surveillance.  Psychological distress prevalence estimates vary as a result of differences in 
sampling frames and measurement approaches, but a meta-analysis published in 2014  reported that 
15–27% of men experience anxiety and 15–18% report depression before and after prostate cancer 
treatment2. Heightened psychological distress is more prevalent in men with locally advanced or 
metastatic prostate cancer compared to men with localized disease 3; risk factors for higher levels of  
distress in men with prostate cancer include young age, comorbidities, and a high symptom burden, 
with the negative effects of domain-specific symptoms on quality of life and mental health increasing 
over time. The Matta et al.1 study suggests that men with localized disease who are managed through 
active surveillance experience better psychological outcomes than those who receive surgery or 
radiation therapy. However, the age (median of 73 years with a range of 71-75), presence of 
comorbidities such as diabetes and hypertension, and receipt of adjuvant treatment in the active 
surveillance cohort suggest that this group also included men who were on watchful waiting and, 
therefore, does not reflect the contemporary practice of active surveillance. In addition, the large 
number of sampling exclusions (for example, only 23% of Ontario-based men on active surveillance 
were included in the study) raises questions about unexplained study bias. These issues, in addition 
to the lack of important clinical data about disease stage, grade, and PSA levels, call for caution in the 
interpretation of the findings1.  
 The interpretation that the report by Matta et al.1 shows a psychological benefit for men on 
active surveillance as opposed to active treatment is simplistic. Analysis of data on antidepressant 
uptake is a blunt tool for understanding the psychological impact of a prostate cancer diagnosis. Each 
treatment or management approach has different demand characteristics, benefits, and costs that 
need to be matched to men’s preferences about their health. Shared decision-making that is informed 
not only by clinical information but also by the active incorporation of men’s values and life 
circumstances is indicated. Men will have different risk profiles for poor or favourable outcomes on 
the basis of their general health, prostate cancer stage, grade of sociodemographic disadvantage, and 
social and support networks, as well as pre-existing physical and psychological health concerns. A 
consideration of these factors by the oncology treatment team is required at all stages of the prostate 
cancer experience.  
 In contrast to the study by Matta and coworkers1, Taylor et al.4 — who used a different 
methodology to track newly diagnosed men with low-risk prostate cancer — found that, over time, 
men on active surveillance had a better physical quality of life with no difference in rates of 
depression, but higher levels of both general and prostate-cancer-specific anxiety, than men on active 
treatment. These findings4 and those of previous research. reference 4 point to the risk of men 
experiencing anxiety about surveillance that not only decreases their overall quality of life but also 
can lead to conversion to active treatment sooner than is clinically indicated. 
 Attention by the health care team to the effective detection and management of psychological 
distress after prostate cancer diagnosis is urgently needed. Men with prostate cancer have an higher 
risk of suicide than age-matched prostate cancer free men, with the first 6–12 months after diagnosis 
being a period of heightened risk5,6; men with locally advanced or metastatic disease and/or single 
marital status are at increased risk. Suicidal ideation has been reported by ~12% of men with prostate 
cancer and can persist for many years7, and one-third of men report a high level of fear of cancer 
recurrence8. Thus, although many men will cope effectively with their prostate cancer experience, 
others will not and the outcome of this psychological distress can be catastrophic. 
 The greatest reductions in the psychological burden in this patient group will likely be gained 
through brief distress screening, which is a well-accepted, but not yet systematically and broadly 
implemented, standard of optimal oncology care. Distress screening has been well validated in men 
with prostate cancer9. A simple single-item scale that measures men’s current levels of distress, which 
has been empirically validated for anxiety, depression, and cancer-specific psychological distress 
reference 9, can be easily incorporated into clinical practice and, when followed by the identification 
and exploration of a patients’ problems, can guide referral for intervention at the required  depth and 
with the correct focus. Importantly, effective psychosocial interventions for men with prostate cancer 
have been identified10. Multimodal psychosocial and psychosexual care for men with prostate cancer 
is acceptable and effective for improving decision‐related distress, mental health, and domain‐specific 
and health‐related quality of life10. Combinations of educational, cognitive behavioural, 
communication, peer support, decision support and relaxation training, have been commonly applied 
and are effective. Face‐to‐face and remote technologies with therapists, nurses, or peer support 
interventions provide a range of mechanisms and sources of support. The key is to identify men with 
psychological distress early and provide psychological and survivorship care in a manner that is 
acceptable to them and responsive to their constructions of masculinity and health and their 
preferences for support. 
 At the very least, the study by Matta et al.1 supports our call for action. After the diagnosis of 
prostate cancer, and regularly throughout treatment and surveillance, men with prostate cancer 
should be screened regularly for psychological distress and referred to evidence-based psychosocial 
intervention, when indicated9. A failure to act and implement high-quality psychological care for men 
with prostate cancer across urology and oncology care settings is not an option. 
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...men with prostate cancer should be screened regularly for psychological distress... 
...failure to act and implement high-quality psychological care for men with prostate cancer ... is not 
an option... 
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